Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Current Deferred Revenue: 2015-2024

Historic Current Deferred Revenue for Intellia Therapeutics (NTLA) over the last 10 years, with Dec 2024 value amounting to $38.9 million.

  • Intellia Therapeutics' Current Deferred Revenue fell 44.63% to $24.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.8 million, marking a year-over-year decrease of 44.63%. This contributed to the annual value of $38.9 million for FY2024, which is 36.19% down from last year.
  • According to the latest figures from FY2024, Intellia Therapeutics' Current Deferred Revenue is $38.9 million, which was down 36.19% from $61.0 million recorded in FY2023.
  • Intellia Therapeutics' Current Deferred Revenue's 5-year high stood at $127.2 million during FY2021, with a 5-year trough of $38.9 million in FY2024.
  • For the 3-year period, Intellia Therapeutics' Current Deferred Revenue averaged around $54.6 million, with its median value being $61.0 million (2023).
  • Per our database at Business Quant, Intellia Therapeutics' Current Deferred Revenue surged by 156.62% in 2020 and then crashed by 49.88% in 2022.
  • Yearly analysis of 5 years shows Intellia Therapeutics' Current Deferred Revenue stood at $73.9 million in 2020, then surged by 72.10% to $127.2 million in 2021, then crashed by 49.88% to $63.8 million in 2022, then fell by 4.36% to $61.0 million in 2023, then plummeted by 36.19% to $38.9 million in 2024.